SEC Form 4 · accession 0001209191-19-018091
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel R Passeri
Officer — CEO and President · Director
Period of report
Mar 6, 2019
Accepted (ET)
Mar 8, 2019 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645460
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 47,600 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.42 | Mar 6, 2019 | A | 125,000 | A | — | Mar 6, 2029 | Common Stock | 125,000 | 125,000 | D |
| Stock Option (right to buy)F2 | $11.54 | Mar 6, 2019 | A | 100,000 | A | — | Jul 23, 2025 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019.
- F2Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions.